● Recruiting

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

Condition: Oropharyngeal Squamous Cell Carcinoma · HPV Positive Oropharyngeal Squamous Cell Carcinoma · Sponsor: Sara Medek

PhasePhase 2

Planned participants31

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.

This description comes directly from the study's public registry record.

Talk to the study team

UCCC Clinical Trials Office · 513-584-7698 · cancer@uchealth.com

Sara Medek, MD

Always discuss trial participation with your own doctor first.

Locations (1)

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07497607